TTI1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: TTI1

NCBI ID: G9675

TTI1

TTI1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Introduction

Alzheimer's disease is a progressive neurological disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. This condition is the most common cause of dementia among older adults, and its symptoms can include memory loss, cognitive decline, and mood disturbances. Currently, there is no cure for Alzheimer's disease, and there are only treatments that can slow down the disease's progression and provide relief from symptoms. As a result, there is a high demand for new and effective treatments that can prevent or reverse the course of this disease.

TTI1: A Potential Drug Target and Biomarker

TTI1 (TELO2 interacting protein 1) is a protein that has been identified as a potential drug target and biomarker for Alzheimer's disease. The TELO2 gene is located on chromosome 12q34 and encodes a protein that is involved in the regulation of axon growth and differentiation.tti1 has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease.

Potential Drug Target

TTI1 has been shown to be involved in the development and progression of neurofibrillary tangles and beta-amyloid plaques, which are the hallmark hallmarks of Alzheimer's disease. Neurofibrillary tangles are composed of abnormal aggregates of the protein tau, which is a tangled and disrupted protein that is involved in the formation of beta-amyloid plaques. The presence of these tangles and plaques is a hallmark of Alzheimer's disease, and they are thought to contribute to the destruction of nerve cells in the brain, leading to the symptoms of this disease.

TTI1 has been shown to be involved in the regulation of several key genes that are involved in the development and progression of neurofibrillary tangles and beta-amyloid plaques. For example, studies have shown that TTI1 interacts with the gene encoding the protein APP, which is a hallmark gene for Alzheimer's disease. This interaction between TTI1 and APP has been shown to play a role in the development of neurofibrillary tangles and beta-amyloid plaques in the brain.

Biomarker

TTI1 has also been shown to be a potential biomarker for Alzheimer's disease. The presence of neurofibrillary tangles and beta-amyloid plaques in the brain is a hallmark of Alzheimer's disease, and the accumulation of these tangles and plaques is thought to contribute to the destruction of nerve cells in the brain. This is why TTI1 has been shown to be a potential biomarker for Alzheimer's disease.

TTI1 has been shown to be involved in the regulation of several key genes that are involved in the development and progression of neurofibrillary tangles and beta-amyloid plaques. For example, studies have shown that TTI1 interacts with the gene encoding the protein APP, which is a hallmark gene for Alzheimer's disease. This interaction between TTI1 and APP has been shown to play a role in the development of neurofibrillary tangles and beta-amyloid plaques in the brain.

Conclusion

TTI1 is a protein that has been identified as a potential drug target and biomarker for Alzheimer's disease. The accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain is a hallmark of

Protein Name: TELO2 Interacting Protein 1

Functions: Regulator of the DNA damage response (DDR). Part of the TTT complex that is required to stabilize protein levels of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family proteins. The TTT complex is involved in the cellular resistance to DNA damage stresses, like ionizing radiation (IR), ultraviolet (UV) and mitomycin C (MMC). Together with the TTT complex and HSP90 may participate in the proper folding of newly synthesized PIKKs. Promotes assembly, stabilizes and maintains the activity of mTORC1 and mTORC2 complexes, which regulate cell growth and survival in response to nutrient and hormonal signals

The "TTI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets